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Dystrophin insufficiency causes selective muscle
histopathology and loss of dystrophin-glycoprotein
complex assembly in pig skeletal muscle
Katrin Hollinger,* Cai X. Yang,* Robyn E. Montz,* Dan Nonneman,† Jason W. Ross,*
and Joshua T. Selsby*,1
*Department of Animal Science, Iowa State University, Ames, Iowa, USA; and †U.S. Department
of Agriculture, Agricultural Research Services, U.S. Meat Animal Research Center, Clay Center,
Nebraska, USA
ABSTRACT The purpose of this investigation was to
determine the extent to which dystrophin insufficiency
caused histomorphological changes in a novel pig
model of Becker muscular dystrophy. In our proce-
dures, we used a combination of biochemical ap-
proaches, including quantitative PCR and Western
blots, along with a histological analysis using standard
and immunohistological measures. We found that 8-wk-
old male affected pigs had a 70% reduction in dystro-
phin protein abundance in the diaphragm, psoas major,
and longissimus lumborum and a 5-fold increase in
serum creatine kinase activity compared with healthy
male littermates. Dystrophin insufficiency in the dia-
phragm and the longissimus resulted in muscle histo-
pathology with disorganized fibrosis that often colocal-
ized with fatty infiltration but not the psoas. Affected
animals also had an 80–85% reduction in -sarcoglycan
localization in these muscles, indicating compromised
assembly of the dystrophin glycoprotein complex. Con-
trols used in this study were 4 healthy male littermates,
as they are most closely related to the affected animals.
We concluded that pigs with insufficient dystrophin
protein expression have a phenotype consistent with
human dystrophinopathy patients. Given that and their
similarity in body size and physiology to humans, we
further conclude that this pig line is an appropriate
translational model for dystrophinopathies.—Hol-
linger, K., Yang, C. X., Montz, R. E., Nonneman, D.,
Ross, J. W., Selsby, J. T. Dystrophin insufficiency causes
selective muscle histopathology and loss of dystrophin-
glycoprotein complex assembly in pig skeletal muscle.
FASEB J. 28, 000–000 (2014). www.fasebj.org
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Dystrophin mutations can result in substantial phys-
ical and locomotion deficits, leading to wheelchair
confinement and early death due to respiratory and/or
cardiac failure. The most severe form, Duchenne mus-
cular dystrophy (DMD), is caused by a lack of dystro-
phin protein. The generally less severe form, Becker
muscular dystrophy (BMD), is caused by insufficient
dystrophin abundance and/or expression of a partially
functional gene product.
Several existing dystrophin-deficient animal models
are currently used in the study of dystrophinopathies.
However, despite the many useful features of the dif-
ferent mouse and dog models a few significant draw-
backs exist. For example, the disease phenotype exhib-
ited by mdx mice is much milder than that of human
patients with DMD (1, 2) in part due to increased
abundance of utrophin, a dystrophin-like protein (3–
5). To mitigate this potential confounding variable,
mdx/utrophin/ mice were developed (5). While the
disease phenotype is more severe in these mice, the
double-knockout approach allows for the possibility
that muscle function and metabolism are affected
independent of the dystrophin mutation. Additional
dystrophin-deficient models with a secondary mutation
have since been developed (5–7). Regardless of mouse
model, there is a poor correlation between effective-
ness of therapies in mouse models to that observed in
human patients (8), as scaling from a mouse to a
human is challenging for a variety of reasons, including
expense, safety, and differences in body size.
In addition to mouse models, a golden retriever
muscular dystrophy (GRMD) model has also been
discovered and is the best characterized of identified
dog models (9). GRMD dogs have a phenotype that is
more similar in severity and in selective muscle injury
compared with human patients than mdx mice (10,
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11). However, GRMD dogs have a high degree of
phenotypic variability (12, 13), and, as in mdx mice,
limited adiposity is observed. Finally, dystrophic dogs
treated with corticosteroids exhibited a greater fre-
quency of calcified necrotic fibers and impairment of
some measures of muscle function (14), which is con-
trary to the beneficial effects of steroid use in human
patients (15). The objective of this project was to
characterize the skeletal muscle phenotype of a re-
cently discovered pig line with a spontaneously occur-
ring substitution in exon 41 of the dystrophin gene
causing an arginine to tryptophan amino acid change.
This substitution leads to decreased dystrophin abun-
dance in skeletal and cardiac muscle (16). To develop
novel therapeutic strategies to treat dystrophinopa-
thies, there must be animal models that accurately
recapitulate the disease. Currently available models
have been useful; however, their inherent limitations
have hindered drug development and approval. The
anatomy, physiology, and genetics of pigs are more
similar to those of humans than are those of mice or
dogs. These similarities increase the likelihood of a
more accurate recapitulation of the human disease and
also mitigate challenges in drug scale-up, as pigs are of
human size. Pigs are currently being used widely for
advancements in human health research (reviewed in
ref. 17), so this suggestion is not unprecedented. In this
report, we detail the early muscle response to dystro-
phin insufficiency in the diaphragm, psoas major, and
longissimus lumborum. Our hope is that dystrophin-
insufficient pigs will aid in the development of thera-
peutic strategies by supplementing currently available
animal models.
MATERIALS AND METHODS
Animal use
All animal procedures were reviewed and approved by the
U.S. Meat Animal Research Center Animal Care and Use
Committee, and procedures for handling pigs complied with
those specified in the Guide for the Care and Use of
Agricultural Animals in Agricultural Research and Teaching.
Animals were housed in 6.5-  8-foot nursery pens by litter
until 8 wk of age. Affected pigs were identified by genotyping
with a Sequenome MassArray system (Sequenome, Inc., San
Diego, CA, USA; ref. 16). At 8 wk of age, 4 male affected pigs
and 4 male healthy littermates were euthanized by electrical
stunning, followed by exsanguination, and 5-g portions of
the medial diaphragm, psoas major, and longissimus lumbo-
rum at the last rib were collected within 15 min of stunning.
Muscles were snap-frozen in liquid nitrogen for biochemical
analyses or frozen in isopentane or fixed in 10% buffered
formalin for histological analyses. Frozen samples were stored
at 80°C until analyzed. The diaphragm was chosen because
it is used in respiration and is a primary cause of mortality in
patients with dystrophinopathy and therefore of importance
for disease progression. The psoas and longissimus were
chosen because of their differing uses and composition of
different fiber types. Specifically, the psoas is generally lightly
used and is comprised largely of type I fibers, while the
longissimus is generally used more frequently and is com-
prised primarily of type II fibers.
Plasma creatine kinase activity
Plasma creatine phosphokinase was measured using a 2-part
reagent system (Pointe Scientific, Canton, MI, USA), follow-
ing the manufacturer’s instructions, in a SpectraMax M5
microplate plate reader (Molecular Devices, Sunnyvale, CA,
USA). Samples (25 l) were measured in duplicate, and the
rate of NADH formation was monitored at 340 nm at 37°C.
Samples having 2500 U/L were diluted in PBS and assayed
again.
mRNA quantification
Muscle samples were powdered with a dry-ice-chilled mor-
tar and pestle. Total RNA was extracted from 50 mg of
powdered muscle using Trizol (Invitrogen, Carlsbad, CA,
USA), following the manufacturer’s instructions with mi-
nor modifications. The RNA was then column purified
(RNeasy Mini Kit, Qiagen, Valencia, CA, USA) to minimize
organic carryover. On the column, and before RNA elu-
tion, DNase digestion (RNase free DNase set; Qiagen) was
used to prevent DNA contamination of the sample. After
quantification using a Nanodrop (Thermo Scientific,
Waltham, MA, USA), 1 g of RNA was reverse-transcribed
(QuantiTect Reverse Transcription Kit; Qiagen) following
the manufacturer’s instructions, with the addition of re-
verse transcription primers for 18S ribosomal RNA. The
18S rRNA does not contain a poly-A tail, and the addition
of the 18S reverse-transcription primers ensures that the
18S rRNA can be converted into cDNA. For quantitative
PCR, equal amounts of cDNA, corresponding to 10 ng of
reverse-transcribed mRNA, were loaded into each well. To
measure gene expression, primer pairs (Table 1) were
mixed together with a QuantiFast SYBR Green PCR kit
(Qiagen) in a reaction volume of 12.5 l, and gene
expression was measured with a Mastercycler EP Realplex
(Eppendorf, Hauppauge, NY, USA). At the end of the PCR
program, melting curves for all amplicons were inspected
to verify that a single product was amplified with each
primer pair. The pig genome has been sequenced and is
well annotated (18), allowing construction of appropriate
primer pairs. All samples were measured in triplicate wells.
Protein extraction
About 500 mg of powdered muscle was added into a glass
Teflon Dounce homogenizer with 0.7 ml extraction buffer
(2% SDS and 10 mM phosphate buffer, pH 7). Following
20 strokes of the homogenizer, the homogenizer was
rinsed with 0.3 ml of extraction buffer, which was collected
into the homogenized sample for a total dilution of 2:1.
Samples were centrifuged at 1500 g for 15 min at room
temperature to remove insoluble material. Protein concen-
tration was measured with the BCA kit (Pierce, Rockford,
IL, USA) at a 1:10 dilution in triplicate. All samples were
diluted to a protein concentration of 3.5 g/l in loading
buffer (62.5 mM Tris, pH 6.8; 2% SDS; 10% glycerol; 2.5%
-mercaptoethanol; and 0.002% bromophenole blue) and
heated to 95°C for 5 min.
Western blot analysis
Protein (35 g; 10 l) was separated at 60 V for 15 min,
followed by 1 h at 120 V in a 4 –20% gradient polyacryl-
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amide gel (Lonza, Rockland, ME, USA). Following separa-
tion, the protein was transferred to a nitrocellulose mem-
brane (GE Water and Process Technologies, Feasterfille-
Trevose, PA, USA) at 90 V for 90 min in the cold room. For
blots intended to detect dystrophin or utrophin, protein
was separated using 6% gels coupled with a 4% stacking
gel. These separations were run at 30 V overnight and then
continued as described previously, with the exception that
PVDF membrane (Millipore, Billerica, MA, USA), rather
than nitrocellulose membrane, was used. In our hands,
PVDF performs better than nitrocellulose for detection of
large proteins. All membranes were stained with Ponceau S
to verify equal loading and transfer. Membranes were
blocked for 30 min with 5% milk in Tris-buffered saline
with 0.1% Tween 20 (TTBS). Membranes were subse-
quently incubated with primary antibody diluted in 1%
milk in TTBS at 4°C overnight as follows: dystrophin
[1:500; rabbit polyclonal (Abcam, Cambridge, MA, USA);
ab15277; aa 3661–3677], -sarcoglycan (1:1000; NCL-L-a-
SARC; Novocastra, Newcastle, UK), and utrophin [1:250;
Developmental Studies Hybridoma Bank (DSHB), Univer-
sity of Iowa, Iowa City, IA, USA; MANCHO3 (8A4) concen-
trate developed by G. E. Morris]. The next day, membranes
were washed 3 times for 10 min in TTBS and incubated in
secondary antibody: donkey anti-rabbit IgG horseradish
peroxidase linked (1:200; GE Healthcare, Little Chalfont,
UK) or sheep anti-mouse IgG horseradish peroxidase
linked (1:2000; GE Healthcare) for 1 h at room tempera-
ture, as appropriate. Membranes were again washed 3
times for10 min with TTBS. After the last wash, ECL
(Millipore) was added to the membranes, and emitted light
was captured with film. To analyze the protein abundance,
the film was scanned and digitized, and band density was
measured using Carestream 5.0 molecular imaging soft-
ware (Carestream Health, New Haven, CT, USA).
Histological staining
Fixed 5-m muscle sections were deparaffinized and rehy-
drated by passing slides through 3 Citrisolv (Fisherbrand,
King of Prussia, PA, USA) baths and 4 ethanol baths with
decreasing percentages of ethanol (100, 100, 95, and 80%).
Hematoxylin and eosin (H&E) staining was performed
according to standard techniques. Briefly, sections were
incubated in Mayer’s hematoxylin, rinsed with tap water,
counterstained with 1% eosin, and dehydrated, and cover-
slips were applied. To perform the trichrome stain, rehy-
drated sections were incubated in Bouin’s solution over-
night at room temperature. The next day, slides were
thoroughly rinsed in tap water and stained with Weigert’s
hematoxylin. Slides were blued with tap water and stained
with Biebrich scarlet. Excess stain was removed with dis-
tilled water before differentiating sections in a phospho-
tungstic/phoshomolybdic acid solution. After differentia-
tion slides were stained with aniline blue. Extra stain was
washed off with distilled water, and sections were differen-
tiated in 1% acetic acid. Finally, acetic acid was rinsed off
with distilled water, sections were dehydrated, and cover-
slips were applied. To assess muscle damage, slides were
coded, and identifying information was removed. In a
blinded fashion, the same trained technician subjectively
sorted the slides according to increasing damage.
TABLE 1. Primer sequences used for quantitative PCR
Primer Sequence Accession number Amplicon length
DMD 5= pig For (exon 9) CCTCGGTTCAAGAGCTATGC NM_001012408 128
DMD 5= pig Rev (exon 10) TCCAACAATGAACTGCCAAA
DMD 5= of SNP pig For (exon 37)a AGCAAACTTGATGGCAAACC NM_001012408 121
DMD 5= of SNP pig Rev (exon 38) AATGGAGGCCTTTCCAGTCT
DMD across SNP pig For (exon 40) TCAGTACAAGAGGCAGGCTG NM_001012408 330
DMD across SNP pig Rev (exon 42) GGCATGTCTTCAGTCATCAC
DMD 3= of SNP pig For (exon 41) AATTTGCTCACTTTCGAAGA NM_001012408 185
DMD 3= of SNP pig Rev (exon 42) GAGGTCAGGAGCATTGAGAA
DMD 3= pig For (exon 62/63) CCACGAGACCCAAACAACTT NM_001012408 153
DMD 3= pig Rev (exon 65) AGGCTCAAGAGATCCAAGCA
TNF pig For GCCCTTCCACCAACGTTTTC NM_214022 158
TNF pig Rev TCCCAGGTAGATGGGTTCGT
IL1B pig For AAGATAACACGCCCACCCTG NM_214055 293
IL1B pig Rev TGTCAGCTTCGGGGTTCTTC
IL6 pig For AGATGCCAAAGGTGATGCCA NM_001252429 363
IL6 pig Rev CTCAGGGTCTGGATCAGTGC
MYOD1 pig For CTACAGCGGTGACTCAGACG NM_001002824 121
MYOD1 pig Rev GCTGTAATAGGTGCCGTCGT
DTNA pig For ACTACCCACGGCAGTTTTTG XM_003356399 110
DTNA pig Rev GCGTGTCCAAGAAACCATTT
SGCA pig For AGGTCGAAAGGAAGGCGTAT NM_001144122 131
SGCA pig Rev CATAGCAGGACAGCAGTGGA
NOS1 pig For GGAAAACAGTCTCCCACCAA XM_003132898 127
NOS1 pig Rev ATCCTGTTCCCAATGTGCTC
UTRN pig For GAACGGATCATTGCTGACCT XM_003121163 177
UTRN pig Rev CCTGAGGAGTTTGGCTTCTG
18S RT primer GAGCTGGAATTACCGCGGCT
18S pig For AAACGGCTACCACATCCAAG NR_046261 141
18S pig Rev TCGCGGAAGGATTTAAAGTG
DTNA, -dystrobrevin; For, forward; IL1B, interleukin 1; IL6, interleukin 6; MYOD1, myogenic differentiation 1; NOS1, (neuronal) nitric
oxide synthase 1; Rev, reverse; SGCA, -sarcoglycan; TNF, tumor necrosis factor; UTRN, utrophin. aGeneBank dbSNP ss410758971.
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Immunohistochemistry (IHC)
Dystrophin expression and localization were measured using
fixed sections. Muscle sections (5 m) were deparaffinized,
and antigen retrieval was performed by heating for 20 min at
95–100°C in Tris-EDTA buffer (10 mM Tris base, 1 mM EDTA
solution, and 0.05% Tween 20, pH 9.0). After cooling to
room temperature and 2 washes in PBS, slides were blocked
with 5% BSA in PBS for 15 min at room temperature.
Following blocking, slides were incubated overnight at 4°C
with mouse monoclonal anti-dystrophin antibody (D8168; aa
1400–1505; Sigma, St. Louis, MO, USA) diluted 1:300 in 5%
BSA. After 3 washes with 0.05% Tween-20 in PBS, sections
were incubated with AlexaFluor 488-labeled goat anti-mouse
IgG (1:100; Invitrogen) for 1 h at room temperature and then
washed again. Slides were mounted with Slowfade Gold
Antifade Reagent with DAPI (Invitrogen). Notably, for all
IHC targets, some sections were incubated without a primary
antibody or without secondary antibody as negative controls.
For detection of desmin, 10-m frozen muscle sections
were washed in PBS for 10 min before blocking with 5% BSA
in PBS at room temperature for 15 min. Sections were
incubated overnight at 4°C with rabbit anti-desmin serum
(1:100; a gift from Dr. Ted Huiatt, Iowa State University,
Ames, IA, USA). The next day, sections were washed 3 times
with PBS and incubated with rhodamine-conjugated donkey
anti-rabbit IgG (1:100; Millipore) for 1 h at room temperature
in the dark. After the secondary incubation, slides were
washed 3 times with PBS, and coverslips were mounted and
sealed as above. To assess dystrophin-glycoprotein complex
(DGC) stability in affected animals and healthy pigs, IHC for
-sarcoglycan (Novocastra, Newcastle, UK) expression and
localization was measured in combination with laminin (Neo-
Markers, Fremont, CA, USA). Sections were treated as de-
scribed previously, and both primary antibodies were used at
a concentration of 1:100. Secondary goat anti-mouse fluores-
cein-conjugated (Millipore) and goat anti-rabbit rhodamine-
conjugated IgG (Millipore) were used at a dilution of 1:100
for 1 h at room temperature in the dark to detect -sarcogly-
can and laminin, respectively.
For analysis of protein abundance following IHC, 2 non-
overlapping 200 pictures were randomly taken from each
section with the appropriate filters. For each protein, images
were collected on the same day for each muscle under
identical exposure conditions in random order and in a
blinded procedure by a technician. Digital images were
transferred to Openlab (Perkin Elmer, Waltham, MA, USA)
so that fluorescence intensity could be measured. The density
slice function was used to transform the image into a binary
image such that pixels were identified as either above or
below threshold intensity. Threshold was determined by
measuring pixel intensity of intracellular and extracellular
areas, as well as at several locations on the sarcolemma in
various random sections. All images were taken and processed
under the same conditions. To measure minimal Feret diam-
eter, the laminin images were converted into binary images as
described above. Images were then exported to the ImagePro
software (MediaCybernetics, Rockville, MD, USA), where the
minimal Feret diameter tool was used to obtain the measure-
ment. The measurements were exported to Excel (Microsoft,
Redmond, WA, USA), where the data were binned and mean
diameter and coefficient of variance were calculated for each
muscle.
For determination of fiber type differences in affected
animals compared with healthy littermates, IHC for slow
myosin (A4.951) was performed in frozen sections in combi-
nation with laminin. The A4.651 serum (DSHB; developed by
H. M. Blau, Stanford University, Stanford, CA, USA) was used
undiluted. Type I myosin heavy chain (MHC) was detected
using fluorescein conjugated goat anti-mouse IgG at 1:100
(Millipore), and laminin was detected as before. Slides were
imaged at 100, which resulted in 200–750 cells/image.
For analyses, both the total number of cells per image and the
number of positive staining cells per image were counted
using ImageJ (19). The cell counts from 2 images/section
were pooled, resulting in 500–1300 cells/section.
Statistics
All data are expressed as means  se unless otherwise noted.
Data were compared using t tests, and significance was set at
P  0.05.
RESULTS
Dystrophin deficiency in pigs with an arginine to
tryptophan (R1958W) substitution
Skeletal muscles from 8-wk-old male pigs with a mis-
sense mutation in the dystrophin gene were compared
with healthy male littermates. Dystrophin protein ex-
pression was decreased by 70% in diaphragm, psoas,
and longissimus collected from affected animals (tryp-
tophan) compared with healthy littermates (arginine)
(Fig. 1A). This decrease was confirmed by 70–90%
reduction in expression by IHC in the diaphragm and
the longissimus but was not significantly different in the
psoas (Fig. 1B, C). Notably, full-length dystrophin pro-
tein was present in all muscles, and it was evenly
localized to the sarcolemma, suggesting that these
muscles are dystrophin insufficient as opposed to dys-
trophin deficient.
To better understand the mechanism leading to
decreased dystrophin protein accumulation, we mea-
sured dystrophin gene expression (Fig. 1D–F and Table
1). Gene expression was similar at the 5= end of the
gene, immediately upstream of the substitution in exon
41, across the substitution, and immediately down-
stream of the substitution in the diaphragm and psoas.
In the longissimus, there was a 50% reduction in gene
expression at all 4 locations. Transcript abundance
amplified by primers designed 3= of the substitution was
significantly lower in the diaphragm, psoas, and longis-
simus by 60, 45, and 70%, respectively, indicating
decreased transcript stability.
Dystrophin insufficiency is associated with muscle
histophatology
Dystrophin insufficiency was associated with a 5-fold
increase in serum creatine kinase activity (Fig. 2A),
which is consistent with other dystrophinopathy models
and human patients with BMD or DMD patients. In
addition, affected and healthy animals could be distin-
guished from one another during histological evalua-
tion (evaluator blinded to the genotype of the animal)
of the diaphragm and longissimus but not the psoas.
Dystrophin insufficiency led to necrotic lesions in dia-
phragm and longissimus muscle, apparent in both
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H&E and trichrome images (Fig. 2B). Evident in these
lesions was disorganized fibrosis and fatty infiltration
that generally colocalized. Immune cell infiltration was
only occasionally present along with immune cell attack
of skeletal muscle cells. Gene expression indicating
inflammation, including tumor necrosis factor (TNF),
interleukin 1 (IL1B), and interleukin 6 (IL6) was
similar between groups in all 3 muscles (Supplemental
Table S1). Notably rare in these muscles was the
appearance of centralized nuclei. Related, myogenic
differentiation 1 (MYOD1) expression was similar be-
tween groups (Supplemental Table S1) for all muscles,
suggesting that satellite cell activation is not wide-
spread. While there were necrotic lesions evident in the
longissimus and diaphragm from affected animals,
there were also areas that appeared similar to healthy
animals (Supplemental Fig. S1).
Mean fiber diameter (minimum Feret diameter) was
similar between healthy and affected pigs across the 3
muscles (Supplemental Fig. S2); however, the variance
coefficient of fiber diameters was increased by20% in
the diaphragm providing an objective measure of mus-
cle injury (Fig. 2C). Variance coefficient of fiber diam-
eter in the psoas and longissimus was similar between
groups.
Dystrophin insufficiency alters expression of DGC
members but not other membrane proteins
In human patients and other animal models, a lack of
dystrophin or insufficient dystrophin expression leads
to a collapse of the DGC. Gene expression of -sar-
coglycan (SGCA), -dystrobrevin (DTNA), and (neuro-
nal) nitric oxide synthase 1 (NOS1; also known as
nNOS) was similar in healthy and affected animals for
all 3 muscles (Supplemental Table S1). Protein expres-
sion by Western blot, however, demonstrated a 50%
reduction in SGCA abundance in all 3 muscles (Fig. 3A).
Such discordant gene and protein expression for
DGC components is consistent with other animal
Figure 1. Dystrophin protein abundance and
localization. Dystrophin was assayed in the dia-
phragm, psoas, and longissimus in muscles
taken from healthy pigs and pigs containing an
arginine to tryptophan (R1958W) polymor-
phism in exon 41 of the dystrophin gene, DMD.
A) By Western blot, dystrophin protein abun-
dance was decreased by 70% in muscles from
diseased animals compared with muscles from
healthy animals. B) Representative 400 im-
ages resulting from IHC targeted to dystrophin.
C) Following fluorescence quantification, dys-
trophin abundance by IHC was significantly
decreased in the diaphragm and longissimus
(P	0.05), but failed to reach significance in the
psoas, in part because variability in the control
animals was high and in part because the
magnitude of change in the psoas was not as
substantial as in the diaphragm and longissi-
mus. D) Dystrophin transcript abundance at 5
locations along DMD in the diaphragm. SNP,
single-nucleotide polymorphism. E) Dystrophin
transcript abundance at 5 locations along DMD
in the psoas. F) Dystrophin transcript abun-
dance at 5 locations along DMD in the longis-
simus. *P  0.05 vs. corresponding control.
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models as well as human patients with DMD (20).
SGCA protein abundance was also measured by IHC
and found to be decreased by 80 – 85% in the dia-
phragm and longissimus, while expression was simi-
lar in the psoas (Fig. 3B, C).
Figure 2. Dystrophin insufficiency leads to muscle injury. A)
Serum creatine kinase activity was increased 4-fold in affected
pigs compared with healthy littermates. B) Representative200
images of slides stained with H&E or trichrome. In a blinded
fashion, diaphragm sections and longissimus sections were suc-
cessfully identified as either from healthy or affected pigs by the
appearance of necrotic lesions, while affected and healthy psoas
muscles were indistinguishable. C) Minimum Feret diameter was
determined on 500–1200 cells/muscle for the diaphragm,
psoas, and longissimus taken from healthy and affected pigs, and
the variance coefficient was calculated. Variance coefficient was
increased in the diaphragm taken from affected animals com-
pared with healthy animals but was similar in the longissimus
and psoas. *P  0.05 vs. corresponding control.
Figure 3. Dystrophin insufficiency leads to a reduction in
-sarcoglycan abundance but not utrophin abundance. A)
Representative Western blot of -sarcoglycan indicating an
50% reduction. B) Representative 400 images for IHC of
-sarcoglycan. C) Fluorescent intensity was quantified and an
80–85% reduction was found in the diaphragm and the
longissimus from affected animals while the psoas was similar
between groups. D) Representative Western blot of utrophin
and quantification. Utrophin was similar between groups.
*P  0.05 vs. corresponding control.
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In addition to SGCA, we also measured abundance
and localization of several other membrane proteins.
Abundance and localization of laminin (Fig. 3 and
Supplemental Fig. S3) and desmin (Supplemental Fig.
S4) were similar between healthy and affected animals
for all 3 muscles. Notably, we found that utrophin gene
expression (Supplemental Table S2), as well as protein
expression, was similar between healthy and affected
pigs for all 3 muscles (Fig. 3D). Hence, these muscles
have a similar loss of expression and organization of the
DGC, as is observed in human patients and other
animal models, without observing compensatory utro-
phin expression, as in the mouse model.
Because in other animal models and human patients
dystrophinopathy is associated with a progressive type I
shift, we measured type I fiber distribution in these
muscles. Surprisingly, at this early time point there was
a 20% increase in type I fibers in the affected dia-
phragms compared with healthy muscle. Fiber type
distribution in the longissimus and psoas was similar
between groups (Fig. 4).
DISCUSSION
Because of inherent limitations in existing animal
models of dystrophinopathy, there has been great
interest in establishing a novel large animal model of
the disease. A genetic line of pigs was recently discov-
ered that was more susceptible to stress-mediated
death. A genome-wide association identified a defect in
the dystrophin gene, which was associated with a reduc-
tion in dystrophin protein accumulation in skeletal
muscle (16). In this investigation, we evaluated the
expression and abundance of dystrophin and DGC
components in diaphragm, psoas major, and longissi-
mus lumborum muscle from healthy and affected 8-wk-
old male pigs. For pigs, the use of the muscles exam-
ined in this study vary greatly in their function, such
that the diaphragm is used during respiration; the
longissimus is a heavily used antigravity muscle and is
involved in transitioning from laying to standing, dur-
ing standing, in shifting weight from one leg to an-
other, and in lying down; the psoas, a hip flexor, is only
lightly used. We found that in these muscles, dystro-
phin protein accumulation was decreased in affected
pigs, as was expression of SGCA, a DGC component,
compared with healthy male littermates. This was asso-
ciated with muscle histopathology consisting of ne-
crotic lesions, fatty infiltration, fibrosis, and increased
fiber-size variability in a muscle specific fashion. Nota-
bly, expression of utrophin, a protein that can substi-
tute for the missing dystrophin protein, was similar
between groups.
At 8 wk of age, affected pigs had a 70% reduction
of DMD in the diaphragm, psoas, and longissimus
compared with healthy littermates that resulted from
a uniform reduction in dystrophin localization to the
sarcolemma. Because each muscle contained residual
full-length dystrophin, these pigs are representative
of a Becker phenotype, not Duchenne. While the
Leiden database does not yet have record of a
BMD-causing missense mutation at this precise loca-
tion, there are numerous documented instances of
missense mutations leading to BMD (21–24). To
better understand the molecular cause of decreased
dystrophin protein accumulation, dystrophin gene
DMD expression was measured using primers against
multiple sites along the DMD gene. Gene expression
in the longissimus was significantly reduced along the
entire gene, while the diaphragm and the psoas only
show a reduction at the 3= end of the gene, suggest-
ing that the point mutation in the dystrophin gene
makes the transcript less stable. This 5=–3= transcript
imbalance also has been observed in patients with
Figure 4. Dystrophin insufficiency alters fiber type distribu-
tion. A) Representative 200 image of IHC for type I MHC.
B) Type I MHC-positive cells were increased 20% in affected
diaphragms compared with diaphragms from healthy ani-
mals, while the psoas and longissimus were similar between
groups. *P  0.05 vs. corresponding control.
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BMD (25). How a substitution in the amino acid
sequence alters susceptibility to proteolysis is un-
known. To gain additional information regarding the
probability of calpain degradation, using CaMPDB
(26), we performed in silico digests of aa 1867–2097,
which is inclusive of the amino acid substitution. We
found that the affected sequence was predicted to be
more susceptible to calpain degradation than se-
quence from control animals. Also, the vastly differ-
ent amino acid properties of arginine and trypto-
phan likely contribute to aberrant protein folding or
a resultant conformational change causing reduced
protein stability (22). Alternatively, altered electro-
static interactions in the rod domain may also destabi-
lize the dystrophin protein (27). These data suggest
that dystrophin insufficiency results from decreased
transcript stability and, speculatively, increased protein
degradation.
Like in other animal models (11, 28, 29) and
human patients (30), failure to accumulate sufficient
dystrophin protein leads to a systemic collapse of
muscle stability, resulting in a 4-fold increase in
serum creatine phosphokinase. H&E and trichrome
staining revealed injury in both the diaphragm and
longissimus of affected animals, including fatty infil-
tration, fibrosis, and necrotic fibers. A progressive
increase in adiposity is a hallmark of dystrophinopa-
thy in human patients (31), although it is not present
in the mdx mouse or the GRMD dog (1). At this early
time point, and similar to muscle from patients, we
did not see accumulation of adipocytes and fibrosis
throughout the entire muscle but rather colocalized
within foci of necrosis. Within these foci, fibrosis and
infiltrating adiposity appeared disorganized, in con-
trast to the high degree of organization found in
healthy regions of muscles from affected animals and
muscles from healthy animals.
Fiber-size variation is another indicator of muscle
injury, and degeneration/regeneration cycles where
larger variance coefficients are indicative of disease
in other animal models and patients with dystrophi-
nopathy (32). Consistent with our subjective histo-
logical evaluation, the objectively measured variance
coefficients in fiber-size distribution were signifi-
cantly increased in diaphragm from affected pigs
compared with healthy littermates. Finally, dystro-
phic muscle undergoes a progressive type I shift as
this fiber type is generally less susceptible to disease-
related injury (33, 34). While unexpected at this early
time point, the frequency of type I fibers was in-
creased in diaphragms from affected animals com-
pared with healthy animals.
Despite being dystrophin insufficient like the dia-
phragm and longissimus, the psoas did not show signs
of increased muscle histopathology, as assessed
through subjective histological evaluation or, more
objectively, by fiber diameter variance. The mechanism
leading to preservation of the psoas is of potential
therapeutic interest. Like in the other muscles investi-
gated, DGC abundance was decreased in psoas from
affected animals; however, localization of DGC compo-
nents was similar. Hence, these data suggest that in the
psoas a greater proportion of these proteins are resi-
dent at the sarcolemma than in the diaphragm or
longissimus. It is reasonable to suggest then that the
similar DGC localization between the psoas from af-
fected and health pigs protects the psoas from injury.
Alternatively, the pattern of use of the psoas in pigs
relative to the diaphragm and longissimus may differ
resulting in less injury and subsequently allowing dys-
trophin accumulation at the sarcolemma. If this were
the case, it would suggest that increased use, such as
during exercise, could hasten disease progression (35,
36). Finally, the psoas is predominantly composed of
type I fibers, which are generally more disease resistant
than type II fibers, and may, therefore, offer protection
from disease.
The absence or reduction of dystrophin protein
accumulation inhibits assembly of the DGC in dystro-
phic muscle (28 –30). In the affected diaphragm,
longissimus, and psoas, gene expression of SGCA,
NOS1, and DTNA was similar to healthy littermates,
which is consistent with other animal models and
human patients (20). Dysregulation becomes appar-
ent when evaluating protein accumulation and local-
ization of these products. Protein expression and
localization of SGCA was decreased in the diaphragm
and longissimus. Surprisingly, the reduction in SGCA
accumulation by Western blot measured in the psoas
was not well matched with expression measured by
IHC. This was consistent, however, with dystrophin
measurement by IHC in this muscle. Collectively,
these observations indicate that in the diaphragm
and longissimus, DGC component proteins are being
translated (albeit less than in healthy muscle) but are
failing to integrate into the membrane. Conversely,
in the psoas, translated DGC components appear to
integrate at an abundance that is similar to healthy
muscle. Apparent DGC fidelity is consistent with
muscle injury, such that, at 8 wk of age, muscle injury
in the diaphragm and longissimus was apparent;
however, the psoas was not distinguishable between
diseased and healthy animals.
In addition, expression and localization of laminin
and desmin were similar between groups, indicating
that there is not a wholesale collapse of membrane
structure. Also, utrophin expression was similar be-
tween groups for all muscles, eliminating one of the
compensatory mechanisms and, hence, limitations
noted in other animal models.
In total, these data indicate that these pigs have
muscle histopathology consistent with a dystrophinopa-
thy. That full-length dystrophin is present at the mem-
brane further implicates these pigs as a novel large
animal model of BMD. Given the genetic, anatomical,
and physiological similarities between pigs and humans
and the fact that these pigs recapitulate many hallmarks
of disease, there is the promise that the BMD pig will
result in a translational disease model capable of filling
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voids left by currently available dystrophinopathy
models.
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